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Our research team previously developed an accelerometry-based device, which can be worn on the 
waist during daily life activities and detects the occurrence of dyskinesia in patients with Parkinson’s 
disease. The goal of this study was to analyze the magnitude of correlation between the numeric output 
of the device algorithm and the results of the Unified Dyskinesia Rating Scale (UDysRS), administered 
by a physician. In this study, 13 Parkinson’s patients, who were symptomatic with dyskinesias, were 
monitored with the device at home, for an average period of 30 minutes, while performing normal daily 
life activities. Each patient’s activity was simultaneously video-recorded. A physician was in charge 
of reviewing the recorded videos and determining the severity of dyskinesia through the UDysRS for 
every patient. The sensor device yielded only one value for dyskinesia severity, which was calculated 
by averaging the recorded device readings. Correlation between the results of physician’s assessment 
and the sensor output was analyzed with the Spearman’s correlation coefficient. The correlation 
coefficient between the sensor output and UDysRS result was 0.70 (CI 95%: 0.33–0.88; p = 0.01). Since 
the sensor was located on the waist, the correlation between the sensor output and the results of the 
trunk and legs scale sub-items was calculated: 0.91 (CI 95% 0.76–0.97: p < 0.001). The conclusion is that 
the magnitude of dyskinesia, as measured by the tested device, presented good correlation with that 
observed by a physician.
Parkinson’s disease (PD) is due to death of dopamine-producing neurons in the brain’s basal ganglia and is char-
acterized by slowness of movement (bradykinesia), together with stiffness and postural instability, sometimes 
also with tremor1. Mild PD responds well to a treatment with L-Dopa and dopaminergic agonists. However, 
as the disease progresses, drug effects wane or last for a shorter time (wearing-off), which requires medication 
dosage adjustments in order to keep the symptoms under control throughout the day2. In spite of this, most 
patients develop motor fluctuations after 10 years. Patients, who have motor fluctuations switch between so-called 
“Off ”-periods – when medication is ineffective and movement is difficult – and so-called “On”-periods – when 
medication is optimally effective and movement is fluid3. Additionally, on the transition between both states (On/
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Off), or during the period of maximum medication effect, patients may present dyskinesias, namely involuntary 
head, trunk or limb movements, which may even interfere with their activity4.
Dyskinesias are a consequence of the dopaminergic treatment, and in many cases they can be improved by 
adjusting the therapeutic schedule. This is difficult for physicians to do, as they are fluctuating symptoms, which 
appear and disappear throughout the daytime, with a hard-to-establish chronology. Currently, to obtain detailed 
information on the time sequence of these symptoms, physicians ask patients to keep written records of the 
times of the day when dyskinesias occur (patient diaries). However, these records also have their limitations, as 
dyskinesia consists of involuntary movements, mostly unperceived by the patient, who often does not recognize 
the moment when the symptom occurs, or forgets to record it. Also, the patient adherence to the method is poor, 
since recording the symptom timeline is a hard task, difficult to complete beyond a few days5. Therefore, an 
automatic monitoring system, capable of recording the timeline of the symptoms would be welcome by both the 
physicians and patients4.
Over the past decade, our research team has been developing a waist worn wearable monitor that detects sev-
eral Parkinson’s symptoms and analyses their evolution over time.
In particular, the device can detect motor fluctuations6,7, bradykinesia8, freezing of gait and dyskinesia9; 
although, dyskinesia is detected in a dichotomous way – namely only its occurrence or not is detected at every 
moment, without information on its severity10. However, the severity of dyskinesia is a useful parameter. In severe 
dyskinesias a therapeutic action is needed, while in milder ones, which do not interfere with the patient’s activity, 
therapeutic adjustments are not necessary. Actually, although the algorithm developed was validated for dichot-
omous results, it produces a continuous numerical value whose magnitude is potentially related to the symptom 
severity and may therefore be useful for clinicians. This study aims at verifying or rejecting the hypothesis that 
the numerical output of the dyskinesia algorithm is correlated with the severity of dyskinesia, as measured with 
a clinical scale.
Methods
This is a concurrent validity study comparing the output of a dyskinesia-detection algorithm, based on acceler-
ometry, with the results of certain subscales of the Unified Dyskinesia Rating Scale (UDysRS)11.
In this study – which is a part of the MoMoPa-III project (Mobility Monitorization of Parkinson patients for 
therapeutic purposes - DTS15/00209 & INV_A088_P) –the inertial signals and video-record database from the 
earlier conducted REMPARK project (Personal Health Device for Remote and Autonomous Management of 
Parkinson’s Disease)12 were used. The REMPARK database was built with the aim of recording inertial signals 
corresponding to different motor symptoms of the Parkinson’s disease: bradykinesia, dyskinesia and freezing 
of gait. The sensor used for recording the REMPARK database was fully developed by the Technical Research 
Centre for Dependency Care and Autonomous Living (CETpD); this sensor records triaxial information, from 3 
integrated inertial sensors (gyroscope, magnetometer and accelerometer), on a microSD card with a 200/second 
sampling frequency.13
The methods used to build the REMPARK database and their rationale, are described elsewhere10,14. Briefly, 
the database was built using a sample of 75 patients with idiopathic Parkinson’s disease, according to the UK 
Parkinson’s Disease Society Brain Bank clinical criteria1. Included patients were at least in a moderate phase of 
the disease (Hoehn and Yahr scale >215) and presented motor fluctuations. Patients older than 80 years, patients 
with gait disorders of a cause other than Parkinson, patients with dementia and patients with implanted elec-
tronic devices were excluded. Patients were selected by convenience sampling among those managed by neu-
rologists in four hospitals: Centro Médico Teknon (Spain), Fondazione Santa Lucia (Italy), Maccabi Healthcare 
Services (Israel) and University Hospital Galway (Ireland). To create the database, ambulatory measures were 
made, at the patients’ home and nearby areas outdoors, using the inertial sensor located on the left side of patients’ 
waist. The data collection protocol was designed to capture dyskinesias, freezing of gait, and motor fluctuations 
while walking around their home and outdoors (free monitoring in real ambient conditions). The protocol also 
included specific daily movements that could be mistaken with Parkinson symptoms, and therefore could cause 
false positive detections to occur: brushing teeth, drying a glass, cleaning a window or a piece of furniture, typ-
ing on the computer and cautiously carrying a glass of water from one room to other. In addition, the system 
records the time periods when patients were sitting or standing while waiting for instruction from the research-
ers. Afterwards, every accelerometer signal segment was identified and tagged according to the corresponding 
activity and symptoms; using the corresponding video recording which was synchronized with the sensor iner-
tial signal. In the particular case of dyskinesias, the associated identification labels included references to the 
body segment involved (head, right leg, left leg, left arm, right arm, trunk) and their severity classified as mild 
or strong according to the opinion of the medical staff reviewing the video records. Besides inertial signals and 
synchronized video records, the database included sociodemographic variables (sex, age) and variables related 
to the Parkinson’s disease for every included patient: year of diagnosis, severity measured with the Hoehn & Yahr 
scale (H&Y)15, therapeutic schedule, Freezing of Gait Questionnaire (FOG-Q) score16 and scores of the Unified 
Parkinson’s Disease Rating Scale (UPDRS) on and off state17.
The Consoric Sanitari del Mresme Ethical Committee approved the research protocol for creating the 
REMPARK database. All participants signed an informed consent form before their inclusion in the study. All 
experiments were performed in accordance with relevant guidelines and regulations.
For the concurrent validity analysis presented in this article, patients presenting dyskinesias from the above 
described database were selected, excluding patients with only mild limb dyskinesia. The reason for excluding 
them is that in video records such dyskinesias are hard to distinguish from voluntary movements, and in some 
cases from tremor; thus, a good reference standard cannot be established for them. The rest of the patients with 
dyskinesias were included in the analysis. For the present study, a physician experienced in movement disor-
ders reviewed the database video records of each patient (which lasted approximately for 30 minutes each) and 
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assessed the severity of dyskinesias with the Part 3 of the UDysRS (Objective evaluation of dyskinesia disability: 
Intensity scale), which rates from 0 to 4 the intensity of the dyskinesia of 7 different body segments. The use of the 
UDysRS was licensed by the International Parkinson and Movement Disorder Society, and the physician received 
training in scale scoring, according to the instrument guidelines. The physician applied the scale at all times on 
the video, when he considered the patients presented dyskinesias. The UDysRS scores for the different video 
scenes were averaged to yield only one dyskinesia score for every patient. Also, the dyskinesia detection algo-
rithm was applied to the inertial signals corresponding to each dyskinesia video scene rated by the physician and 
the results averaged to obtain a single value per patient. Due to privacy reasons, the participants’ faces were not 
recorded in many videos, thus the face dyskinesia item on the scale was not assessed or included in the analysis. 
The expert who reviewed the video-records had no access to the algorithm information.
The dyskinesia algorithm is based on frequency analysis and on the principle that low-frequency 
low-amplitude harmonics appear in movement inertial records of patients with dyskinesia10. According to this 
principle, while the patient is still (while sitting or standing up) characteristic harmonics appear in the signals, 
which are due to dyskinesia. In a simple way, the method considers the power spectrum in the frequency band, 
which is composed of harmonics 1–4 Hz – called the dyskinesia band – to detect dyskinesia. Furthermore, several 
more conditions are considered, which allow for better contextualization of a patient’s movements and conse-
quently improve algorithm specificity. This article is focused on the lowest level of the algorithm previously pub-
lished10, which analyses the signal’s 50% overlapped windows. The window’s length was selected on the basis of 
three key factors: the lowest limit of the frequency bands of interest – in this case 1 Hz – the sampling frequency 
– fixed at 40 Hz – and finally, the use of temporal values which are a power of two, a technical requirement to be 
able to use fast conversion Fast Fourier Transform (FFT) algorithms. Taking these three factors into account, 3.2 
second-windows, or 128 sample-windows, were the most suitable choice. Thus, a characteristic value per window 
was obtained every 1.6 seconds, which resulted from the addition of the power spectrum of the harmonics asso-
ciated to the dyskinesia band.
In summary, the accelerometer measurements are divided into windows of 3.2 seconds (50% overlapping) and 
the only characteristic used is the sum of the power spectrum in the dyskinesia frequency band of the three axes. 
An average is calculated from the vector, of this characteristic, incorporating the multiple relevant windows eval-
uated (the evaluations are only carried out when the patient is still). For example, if the physician has performed 
an evaluation of the UDysRS in a period comprised between the 120 and 240 seconds of a video, the output value 
of the dyskinesia algorithm is the average of the characteristics from the vector comprised between these seconds 
where the patient is still. In Fig. 1, a schematic representation of the data analysis is presented.
In the statistical analysis, the numerical value from the dyskinesia algorithm was compared with the UDysRS 
scale value by using the Spearman’s correlation coefficient. Every patient contributed to the calculation of this 
correlation coefficient with only one sensor output (the mean characteristic value from the windows included in 
the scenes rated by the physician) and only one UDysRS score (the mean of the physician’s scores). Correlation 
was first calculated with the total available UDysRS scores and, subsequently, using only with the trunk and 
lower-limb items since, given the sensor’s location on the body, it can be hypothesized that the correlation with 
such body segments would be better. The confidence interval for Spearman correlation was calculated by applying 
the Fisher transformation18.
The datasets generated and analyzed during the current study are available from the corresponding author on 
reasonable request.
Results
The study included 13 patients, of which 8 were labeled in the database as with “mild trunk dyskinesias”, 3 were 
labeled as “severe trunk dyskinesias” and 2 patients as “severe limb dyskinesias”. Table 1 shows the demographic 
and clinical characteristics of included patients. A total of 6 hours of video (mean of 28 minutes per patient) were 
analyzed by the expert clinician. On average, the UDysRS scale was administered by the expert observer 7 times 
per video record.
The correlation between the mean UDysRS score for each patient and the sensor output was 0.70 (CI 95%: 
0.33-0.88; p = 0.01). When only the mean trunk and lower-limb UDysRS scores from each patient were used, the 
correlation with the sensor output increased to 0.91 (CI 95% 0.76–0.97: p < 0.001). Figures 2 and 3 illustrate the 
correlation results. Table 2 details the correlation coefficient for every analyzed scale item.
Figure 1. Schematic representation of the signal treatment and the statistical analysis process.
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Discussion
In this study, the output of a dyskinesia-detection algorithm, previously developed by the authors, was found to be 
well correlated with the UDysRS scale (objective evaluation of dyskinesia disability: Intensity scale), specifically 
with the items related to trunk and lower-limb dyskinesias.
Experimental work has been done regarding detection of dyskinesias with inertial sensors (occurrence 
vs. non-occurrence of dyskinesia), which have been previously discussed by us10. However, few studies have 
addressed detection of the severity of dyskinesias. Keijsers et al.19, monitored 13 patients in a “home-like” situa-
tion, at the Occupational Therapy Department of the University Medical Center for 2.5 hours, using 6 accelerom-
eters, located on different parts of the body. When they used the data from the whole sensor network they found 
good correlation with the outcome of the Abnormal Involuntary Movement Scale (AIMS). However, correlation 
between the scale and the different sensors individually was low (between 0.37 and 0.44); thus none of them alone 
was enough to detect the severity of dyskinesia. Devices based on multiple sensors distributed on the whole body 
are hard to use in clinical practice or for long monitoring periods; thus, our system has higher potential to be 
transferred to the clinical practice.
Hoff JI et al.20 conducted an experiment with 4 pairs of biaxial accelerometers, located on body segments of the 
side of the body, which was most affected by the Parkinson’s disease. As a comparison standard, they used video 
records and the Abnormal Involuntary Movement Scale (AIMS). They found good correlation between the sensor 
and the clinical scale (0.8–0.87), although only with the patient at rest or doing highly protocolized movements, 
and with sensors located on body segments that did not participate in movement. Thus, their results are also 
not applicable to patients’ daily life or to clinical practice. Similarly, Manson et al.21 found that patients with the 
highest AIMS scores had a larger frequency component in the 1–3 Hz band; however, they only measured during 
particular protocolized activities, in highly controlled situations; thus, their results do not seem to extrapolate 
to ambulatory measurement required in the clinical practice. Lopane et al.22 studied dyskinesia in 13 patients, 
Age Sex H&Ya










1 77 Male 2.5 <25 13 27 700 39 17
2 75 Male 3.0 <25 14 16 600 34 20
3 65 Male 3.0 25–50 14 8 650 43 16
4 60 Male 2.5 25–50 17 17 800 23 5
5 66 Male 4.0 50–75 17 11 900 38 8
6 73 Male 2.5 <25 9 500 26
8 74 Female 3.0 <25 11 27 625 65 33
9 65 Female 3.0 25–50 20 18 825 56 15
10 74 Female 2.5 <25 20 26 500 48 16
11 71 Female 3.0 <25 16 11 875 27 10
12 73 Female 3.0 <25 13 11 1200 49 16
13 67 Male 3.0 25–50 14 24 1100 44 5
Average 70 2.9 38 15 18 773 41 15
Table 1. Demographic and health data of the participants. aHoehn & Yahr scale. bAs reported in the Unified 
Parkinson’s Disease Rating Scale. cFreezing of Gait Questionnaire. dUnified Parkinson’s Disease Rating Scale. 
*Basal data from participant number 7 were unavailable in the database.
Figure 2. Correlation of total Unified Dyskinesia Rating Scale score with sensor output.
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who were standing still with eyes open, and found lower correlation than that described here, with their inertial 
sensors. Ramsperger R. et al.23 used gyroscopes to analyze the movement of 7 patients with leg dyskinesia at the 
laboratory and found low correlation with the Unified Dyskinesia Rating Scale (0.61). Although these authors 
completed the study with an experiment conducted in a real-world environment, they did not estimate the sever-
ity of dyskinesia in this part of the study, but just detected its occurrence. No further studies were found, where 
the severity of dyskinesia was estimated during natural patients’ activity outside the laboratory. Therefore, the 
work described in this paper is original in this regard. We postulate that inertial systems for symptom detection in 
Parkinson’s patients should be validated under real conditions of use, because the large amount of movements a 
person makes during daily life activity cannot be sufficiently studied through laboratory protocols or by assessing 
only predetermined movements of patients.
The algorithm used in this research, was earlier demonstrated to be valid for detection of dyskinesias; now, it 
is clear that its numerical output is also correlated with dyskinesia magnitude. However, the algorithm does not 
measure the occurrence of dyskinesias in a continuous way, but measurements are automatically discontinued if 
activities which interfere with detection occur (walking or changing position). This apparent limitation is actually 
a strong point, because it enables the disregarding of false-positive detections, when the sensor is used in real life 
conditions, with a huge variety of possible movements that can be mistaken for dyskinesias. Furthermore, the 
amount of data missed because of such an automatic discontinuation is often small, since most people, especially 
Parkinson’s patients, spend most daytime in relative rest, either standing up or sitting down.
Our study has some limitations such as the small tested-patient sample or the short monitoring time. It is hard 
to increase the monitoring time because, since the gold standard is a video record, it is hard to video-monitor 
patients for many hours. This might contribute to the scarcity of studies where dyskinesia is assessed with sensors 
and its severity is estimated (since this requires continuous observation). Such a short monitoring time is partly 
compensated by the fact that patients were asked to perform daily-life activities, in order to test the sensor.
The small sample size, similar to the other works discussed above, was sufficient to determine the high correla-
tion in particular with the trunk and lower-limb UDysRS scores, within a reasonably narrow confidence interval.
Figure 3. Correlation of lower-limb Unified Dyskinesia Rating Scale scores with sensor output.
Item Ro p-value
1.- Face NaN NaN
2.- Neck 0.39 0.396
3.- Right arm 0.25 0.430
4.- Left arm 0.53 0.148
5.- Trunk 0.64 0.021
6.- Right leg 0.77 0.014
7.- Left leg 0.70 0.021
Items: 5 + 6 + 7 0.91 <0.001
Total 0.70 0.010
Table 2. Spearman’s correlation between the dyskinesia algorithm and the Unified Dyskinesia Rating Scale. 
Bold type: statistically significant finding.
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Patients categorised as “mild dyskinesia of the limb” were excluded from the study; thus, the algorithm was 
not tested on such patients. Rather than a limitation of the algorithm, this is a limitation of the reference standard, 
because mild dyskinesia of the limbs is very hard to distinguish from voluntary movements or tremor, making 
comparison with the algorithm’s results unreliable.
In conclusion, the presented algorithm, which had previously shown good validity for detection of dyskine-
sia in real life conditions, does yield values that correlate with its severity and can therefore be useful to detect 
patients with severe dyskinesia. Given that the algorithm uses the signal from only one low energy inertial sensor, 
which can be comfortably worn on the waist, and given that it has been validated in real conditions of use, it has 
the potential to be used in clinical practice to help identify patients, who need therapy adjustment due to their 
dyskinesias.
References
 1. Hughes, A. J., Daniel, S. E., Kilford, L., Lees, A. J. & Daniel, S. E. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a 
clinico-pathological study of 100 cases. Neurosurgery, and Psychiatry 55, 181–184 (1992).
 2. Fahn, S. et al. Levodopa and the Progression of Parkinson’s Disease. N. Engl. J. Med. 351, 2498–2508 (2004).
 3. Ahlskog, J. E. & Muenter, M. D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative 
literature. Mov. Disord. 16, 448–58 (2001).
 4. Fabbrini, G., Brotchie, J. M., Grandas, F., Nomoto, M. & Goetz, C. G. Levodopa-induced dyskinesias. Mov. Disord. 22, 1379–1389 
(2007).
 5. Papapetropoulos, S. S. Patient Diaries As a Clinical Endpoint in Parkinson’s Disease Clinical Trials. CNS Neurosci. Ther. 18, 380–387 
(2012).
 6. Rodríguez-Molinero, A. et al. Validation of a portable device for mapping motor and gait disturbances in Parkinson’s disease. JMIR 
mHealth uHealth 3, e9 (2015).
 7. Rodríguez-Molinero, A. et al. A kinematic sensor and algorithm to detect motor fluctuations in Parkinson disease: Validation study 
under real conditions of use. J. Med. Internet Res. 20 (2018).
 8. Samà, A. et al. Estimating bradykinesia severity in Parkinson’s disease by analysing gait through a waist-worn sensor. Comput. Biol. 
Med. 84 (2017).
 9. Rodríguez-Martín, D. et al. Home detection of freezing of gait using Support Vector Machines through a single waist-worn triaxial 
accelerometer. PLoS One 12 (2017).
 10. Pérez-López, C. et al. Dopaminergic-induced dyskinesia assessment based on a single belt-worn accelerometer. Artif. Intell. Med. 67 
(2016).
 11. Goetz, C. G., Nutt, J. G. & Stebbins, G. T. The Unified Dyskinesia Rating Scale: Presentation and clinimetric profile. Mov. Disord. 23, 
2398–2403 (2008).
 12. Samà, A. et al. A double closed loop to enhance the quality of life of Parkinson’s Disease patients: REMPARK system. in Studies in 
Health Technology and Informatics 207 (2014).
 13. Rodríguez-Martín, D., Pérez-López, C., Samà, A., Cabestany, J. & Català, A. A wearable inertial measurement unit for long-term 
monitoring in the dependency care area. Sensors (Basel). 13, 14079–104 (2013).
 14. Parkinson’s Disease Management through ICT: The REMPARK Approach. (River Publishers, 2017).
 15. Hoehn, M. M. & Yahr, M. D. Parkinsonism: onset, progression and mortality. Neurology 17, 427–42 (1967).
 16. Giladi, N. et al. Validation of the freezing of gait questionnaire in patients with Parkinson’s disease. Mov. Disord. 24, 655–61 (2009).
 17. Goetz, C. G. et al. Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): 
Scale presentation and clinimetric testing results. Mov. Disord. 23, 2129–2170 (2008).
 18. Fisher, R. A. Frequency Distribution of the Values of the Correlation Coefficient in Samples from an Indefinitely Large Population. 
Biometrika 10, 507 (1915).
 19. Keijsers, N. L. W., Horstink, M. W. I. M. & Gielen, S. C. A. M. Automatic assessment of levodopa-induced dyskinesias in daily life by 
neural networks. Mov. Disord. 18, 70–80 (2003).
 20. Hoff, J. I., van den Plas, A. A., Wagemans, E. A. & van Hilten, J. J. Accelerometric assessment of levodopa-induced dyskinesias in 
Parkinson’s disease. Mov. Disord. 16, 58–61 (2001).
 21. Manson, A. J. et al. An ambulatory dyskinesia monitor. J Neurol Neurosurg Psychiatry 68, 196–201 (2000).
 22. Lopane, G. et al. Dyskinesia detection and monitoring by a single sensor in patients with Parkinson’s disease. Mov. Disord. 30, 
1267–1271 (2015).
 23. Ramsperger, R. et al. Continuous leg dyskinesia assessment in Parkinson’s disease -clinical validity and ecological effect. Park. Relat. 
Disord. 26, 41–46 (2016).
Acknowledgements
This study was supported by the Monitoring the Mobility of Parkinson’s Patients for Therapeutic Purposes Project 
(DTS15/00209), funded by the Instituto de Salud Carlos III–Ministerio de Economía y Competitividad and the 
European Regional Development Fund. The database used in the study was built within the REMPARK project 
(ICT-287677), which was funded by the European Commission. We would like to thank Dr. Antonio Yuste 
and Ms. Esther Valldosera for helping with the research management and administration, and Dr. John Nelson 
(University of Limerick) for proofreading the manuscript.
Author Contributions
A.R.M. conceived the study, designed the study and drafted the first version of the manuscript. C.P.L. contributed 
to the study design, and performed algorithmic work and statistical analysis. He contributed to and approved 
the final version of the manuscript. A.S., D.R.M. and M.M.A. contributed to the database design, performed 
algorithmic work, and approved the final version of the manuscript. S.A., B.A., B.M., P.Q., B.G., G.V., P.B., D.S. and 
L.Q. performed the field work for building the database and approved the final version of the manuscript. A.B., 
H.L., A.C., R.A., T.C., G.O.L. and J.C. contributed to the database design and data collection in their respective 
study site. They approved the final version of the manuscript.
7Scientific RepoRtS |         (2019) 9:13434  | https://doi.org/10.1038/s41598-019-49798-3
www.nature.com/scientificreportswww.nature.com/scientificreports/
Additional information
Competing Interests: Alejandro Rodríguez-Molinero, Albert Samà, Carlos Pérez-López, Juan Manuel Moreno 
and Joan Cabestany are shareholders of Sense4Care which is a spin-off company, which may commercialize 
the results of this research device in the near future. These authors declare that the possible commercialization 
of the product is a research outcome; and the design, the analysis, the interpretation of the results or the 
conclusions are not affected by commercial interests. Daniel Rodríguez-Martín, presently works at Sense4Care, 
his relation with the company started after this study was finished.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
